---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-090761"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:12:57.684034+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Terns Q2 net loss $22.7M; cash $225M; TERN-601 Ph1 data Sep, TERN-701 data Dec 2024

## Summary
- Net loss of $22.7M for Q2 2024 ($0.31/share) vs $17.9M ($0.25/share) in Q2 2023.
- Cash, equivalents and marketable securities $225.3M, expected to fund operations into 2026.
- Top-line Phase 1 data for oral GLP-1 TERN-601 (obesity) expected September 2024.
- Interim Phase 1 CARDINAL trial data for allosteric BCR-ABL TERN-701 (CML) expected December 2024.
- Appointed Elona Kogan as CLO; CFO search underway; Mark Vignola to serve through Jan 2025.

## SEC filing metadata
- accession: 0000950170-24-090761
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017024090761/0000950170-24-090761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017024090761/tern-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-090761
- JSON: https://secwatch.observer/filing/0000950170-24-090761.json
- Plain text: https://secwatch.observer/filing/0000950170-24-090761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.